Dr. Mastrangelo

Michael J. Mastrangelo, MD

Contact Dr. Mastrangelo

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma
  2. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  3. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells
  4. Intralesional therapy for in-transit and satellite metastases in melanoma
  5. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
  6. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  7. Altered drainage patterns in patients with melanoma and previous axillary dissection
  8. A pilot study of sunitinib malate in patients with metastatic uveal melanoma
  9. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
  10. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  11. Defining the critical hurdles in cancer immunotherapy
  12. Masthead
  13. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy
  14. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine
  15. In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2
  16. Conjunctival melanoma: Bladder and upper urinary tract metastases
  17. The wrath of RAFs: Rogue behavior of B-RAF kinase inhibitors
  18. Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the ampulla of vater
  19. The Role of Anti-Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit?
  20. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: Immunoadhesins for human IL-10 with therapeutic potential